If not administered properly, health experts say medications like Ozempic, Mounjaro, and Wegovy can cause gastrointestinal ...
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.
GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.
New Dietary Recommendation for Managing Gastrointestinal Issues Treated with GLP-1 Receptor Agonists
A recent commentary article published in Diabetes, Metabolic Syndrome and Obesity provides dietary recommendations for individuals using GLP-1 receptor agonists (GLP-1RAs ... reducing energy intake ...
HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...
For adults, about half think it’s a good thing, and about 2 in 10 think it’s a bad thing. The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, ...
I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets ... them in 2024 — are expected to dominate a weight loss industry worth >$150bn by 2030.
More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results